



Renáta Váraljai

Contact

Renáta Váraljai

Publications (2)

Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. *Nat Cancer* 2023; 4:1395.

Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht L, Shannan B, Brase J, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt H, Dick J, Engel D, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke J, Klose J, Fendler W, Thommen D, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. *Nat Cancer* 2023; 4:1292-1308.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch